IART Quote, Financials, Valuation and Earnings

LeMaitre Vascular has a net margin of -6.61% compared to Integra Lifesciences Holdings's net margin of 18.39%. Integra Lifesciences Holdings's return on equity of -1.88% beat LeMaitre Vascular's return on equity of 13.74%.

Integra Lifesciences Holdings has a consensus price target of $16.13, signalling upside risk potential of 32.61%. On the other hand LeMaitre Vascular has an analysts' consensus of $104.50 which suggests that it could grow by 28.81%. Given that Integra Lifesciences Holdings has higher upside potential than LeMaitre Vascular, analysts believe Integra Lifesciences Holdings is more attractive than LeMaitre Vascular.

Integra Lifesciences Holdings has a beta of 1.164, which suggesting that the stock is 16.396% more volatile than S&P 500. In comparison LeMaitre Vascular has a beta of 0.827, suggesting its less volatile than the S&P 500 by 17.35%.

Integra Lifesciences Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. LeMaitre Vascular offers a yield of 0.89% to investors and pays a quarterly dividend of $0.20 per share. Integra Lifesciences Holdings pays -- of its earnings as a dividend. LeMaitre Vascular pays out 32.65% of its earnings as a dividend. LeMaitre Vascular's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Integra Lifesciences Holdings quarterly revenues are $382.7M, which are larger than LeMaitre Vascular quarterly revenues of $59.9M. Integra Lifesciences Holdings's net income of -$25.3M is lower than LeMaitre Vascular's net income of $11M. Notably, Integra Lifesciences Holdings's price-to-earnings ratio is 70.14x while LeMaitre Vascular's PE ratio is 40.97x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Integra Lifesciences Holdings is 0.57x versus 8.19x for LeMaitre Vascular. Usually stocks with elevated PS ratios are considered overvalued.

Outset Medical has a net margin of -6.61% compared to Integra Lifesciences Holdings's net margin of -86.66%. Integra Lifesciences Holdings's return on equity of -1.88% beat Outset Medical's return on equity of -140.06%.

Integra Lifesciences Holdings has a consensus price target of $16.13, signalling upside risk potential of 32.61%. On the other hand Outset Medical has an analysts' consensus of $26.50 which suggests that it could grow by 32.77%. Given that Outset Medical has higher upside potential than Integra Lifesciences Holdings, analysts believe Outset Medical is more attractive than Integra Lifesciences Holdings.

Integra Lifesciences Holdings has a beta of 1.164, which suggesting that the stock is 16.396% more volatile than S&P 500. In comparison Outset Medical has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Integra Lifesciences Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Outset Medical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Integra Lifesciences Holdings pays -- of its earnings as a dividend. Outset Medical pays out -- of its earnings as a dividend.

Integra Lifesciences Holdings quarterly revenues are $382.7M, which are larger than Outset Medical quarterly revenues of $29.8M. Integra Lifesciences Holdings's net income of -$25.3M is higher than Outset Medical's net income of -$25.8M. Notably, Integra Lifesciences Holdings's price-to-earnings ratio is 70.14x while Outset Medical's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Integra Lifesciences Holdings is 0.57x versus 0.75x for Outset Medical. Usually stocks with elevated PS ratios are considered overvalued.

Insulet has a net margin of -6.61% compared to Integra Lifesciences Holdings's net margin of 6.22%. Integra Lifesciences Holdings's return on equity of -1.88% beat Insulet's return on equity of 36.9%.

Integra Lifesciences Holdings has a consensus price target of $16.13, signalling upside risk potential of 32.61%. On the other hand Insulet has an analysts' consensus of $334.74 which suggests that it could grow by 9.89%. Given that Integra Lifesciences Holdings has higher upside potential than Insulet, analysts believe Integra Lifesciences Holdings is more attractive than Insulet.

Integra Lifesciences Holdings has a beta of 1.164, which suggesting that the stock is 16.396% more volatile than S&P 500. In comparison Insulet has a beta of 1.375, suggesting its more volatile than the S&P 500 by 37.475%.

Integra Lifesciences Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insulet offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Integra Lifesciences Holdings pays -- of its earnings as a dividend. Insulet pays out -- of its earnings as a dividend.

Integra Lifesciences Holdings quarterly revenues are $382.7M, which are smaller than Insulet quarterly revenues of $569M. Integra Lifesciences Holdings's net income of -$25.3M is lower than Insulet's net income of $35.4M. Notably, Integra Lifesciences Holdings's price-to-earnings ratio is 70.14x while Insulet's PE ratio is 54.79x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Integra Lifesciences Holdings is 0.57x versus 10.25x for Insulet. Usually stocks with elevated PS ratios are considered overvalued.

Teleflex has a net margin of -6.61% compared to Integra Lifesciences Holdings's net margin of 13.56%. Integra Lifesciences Holdings's return on equity of -1.88% beat Teleflex's return on equity of 3.41%.

Integra Lifesciences Holdings has a consensus price target of $16.13, signalling upside risk potential of 32.61%. On the other hand Teleflex has an analysts' consensus of $155.92 which suggests that it could grow by 30.01%. Given that Integra Lifesciences Holdings has higher upside potential than Teleflex, analysts believe Integra Lifesciences Holdings is more attractive than Teleflex.

Integra Lifesciences Holdings has a beta of 1.164, which suggesting that the stock is 16.396% more volatile than S&P 500. In comparison Teleflex has a beta of 1.098, suggesting its more volatile than the S&P 500 by 9.761%.

Integra Lifesciences Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Teleflex offers a yield of 1.13% to investors and pays a quarterly dividend of $0.34 per share. Integra Lifesciences Holdings pays -- of its earnings as a dividend. Teleflex pays out 91.2% of its earnings as a dividend. Teleflex's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Integra Lifesciences Holdings quarterly revenues are $382.7M, which are smaller than Teleflex quarterly revenues of $700.7M. Integra Lifesciences Holdings's net income of -$25.3M is lower than Teleflex's net income of $95M. Notably, Integra Lifesciences Holdings's price-to-earnings ratio is 70.14x while Teleflex's PE ratio is 37.83x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Integra Lifesciences Holdings is 0.57x versus 1.86x for Teleflex. Usually stocks with elevated PS ratios are considered overvalued.